Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions
Open Access
- 26 April 2007
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 21 (8), 1827-1828
- https://doi.org/10.1038/sj.leu.2404711
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Treatment of deletion 5q acute myeloid leukemia with lenalidomideLeukemia, 2007
- Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor CellsCancer Research, 2007
- Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q DeletionNew England Journal of Medicine, 2006
- Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndromeLeukemia, 2006
- Lenalidomide therapy in myelofibrosis with myeloid metaplasiaBlood, 2006
- Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assemblyLeukemia Research, 2006
- X-inactivation–based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesisBlood, 2006
- Efficacy of Lenalidomide in Myelodysplastic SyndromesNew England Journal of Medicine, 2005